Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Chainbing (CBG) Trading 11.1% Lower This Week
Chainbing (CBG) traded 3.3% lower against the dollar during the 24-hour period ending at 8:00 AM E.T. on January 9th....
Chainbing (CBG) Trading 11.1% Lower This Week
Chainbing (CBG) traded 3.3% lower against the dollar during the 24-hour period ending at 8:00 AM E.T. on January 9th....
KuCoin Token (KCS) Market Cap Tops $1.27 Billion
KuCoin Token (KCS) traded 0.7% lower against the dollar during the one day period ending at 8:00 AM Eastern on...
KuCoin Token (KCS) Market Cap Tops $1.27 Billion
KuCoin Token (KCS) traded 0.7% lower against the dollar during the one day period ending at 8:00 AM Eastern on...
Evercore ISI Boosts Viper Energy (NASDAQ:VNOM) Price Target to $58.00
Viper Energy (NASDAQ:VNOM – Free Report) had its price objective raised by Evercore ISI from $45.00 to $58.00 in a...
Evercore ISI Boosts Viper Energy (NASDAQ:VNOM) Price Target to $58.00
Viper Energy (NASDAQ:VNOM – Free Report) had its price objective raised by Evercore ISI from $45.00 to $58.00 in a...